治疗性乙型肝炎疫苗研究进展  

Research advances in therapeutic vaccination against hepatitis B virus

作　　者：李计来(综述)[1] 许丽锋(审校)[1] 徐静(审校)[1] 

机构地区：[1]北京生物制品研究所免疫研究室,100024

出　　处：《国际生物制品学杂志》2010年第3期148-152,共5页International Journal of Biologicals

摘　　要：全球范围内有超过4亿慢性乙型肝炎病毒携带者，这些患者发展为肝硬化和肝癌的危险性较大。现有疗法不能长期控制大多数患者的病毒复制，而治疗性乙型肝炎疫苗因其独特的优点正成为新的研究热点。此文就治疗性乙型肝炎疫苗的分类及最新研究进展加以综述。More than 400 million people in the world are now chronically infected with hepatitis B virus（HBV）. For these patients, there is a high risk to develop cirrhosis and hepatocellular carcinoma. Currently available therapies fail to control viral replication for a long time in most patients. Vaccine therapy has recently shown a unique advantage and become the development focus for treatment of patients with chronic HBV infection. This paper reviews the classification and recent research progress of therapeutic HBV vaccines.

关 键 词：肝炎疫苗 乙型 治疗 肝炎表面抗原 乙型 肝炎核心抗原 乙型 

分 类 号：R512.62[医药卫生—内科学]